268P - What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Metastatic
Breast Cancer
Presenter Preeti Bajaj
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors P. Bajaj1, D. Latremouille-Viau2, A. Guerin2, C. Reyes1, A. Stein1, A. Kurian3, P. Cortazar1
  • 1Us Medical Affairs, Genentech Inc. - Roche - USA, 94080 - South San Francisco/US
  • 2Analysis Group, Analysis Group, H3B 4W5 - Montreal/CA
  • 3Division Of Oncology, Stanford University School of Medicine, 94305 - Stanford/US

Abstract

Background

mTNBC is a condition with significant unmet medical need due to limited treatment (tx) options and short survival after chemotherapy (chemo) failure. Tx patterns and OS in patients (pts) with mTNBC in US clinical practice were assessed.

Methods

This retrospective chart review study used data collected in October and November 2016 from US oncologists via an online case report form. Data of adult pts who were initiated on a pharmacological tx after a diagnosis of recurrent or de novo mTNBC between January 2012 and June 2015 were reviewed. Tx regimens used in 1st- and 2nd-lines for mTNBC were summarized. Median OS from 1st- and 2nd-line tx initiation were estimated using Kaplan-Meier analyses.

Results

125 oncologists provided data on 411 mTNBC pts; mean age was 57 years; 298 (73%) had ≥2 lines of tx; 256 different tx sequences were identified. Mean duration of tx was 7.5 months (mos) in 1st-line and 7.3 mos in 2nd-line. The most prevalent tx regimens were single agent chemo with taxane (22%) in 1st-line and capecitabine (Cap; 20%) in 2nd-line. Median OS was 16.7 mos in 1st-line and 14.2 mos in 2nd-line.Table:

268P

1st-line, N = 411%Median OS [95% CI], mos
All-16.7 [15.2; 18.0]
Single agent4515.6 [13.2; 18.6]
Combination5517.0 [15.1; 19.1]
Tx regimen
Single agent taxane (docetaxel/paclitaxel (pac)/nab-pac)22
Anthracycline (ATC; doxorubicin [Dox]/epirubicin/liposomal Dox) + cyclophosphamide +/- taxane14
Platinum (carboplatin/cisplatin/oxaliplatin) + taxane13
Bevacizumab-containing10
Gemcitabine (Gem) + platinum10
Cap9
Other21
2nd-line, N = 298
All-14.2 [10.5; 22.3]
Single agent7212.9 [10.5; 22.3]
Combination2816.2 [8.1; -]
Tx regimen
Cap20
Platinum-containing (w/o taxane)13
Single agent taxane13
Taxane-containing combination12
Eribulin9
ATC-containing (w/o taxane or platinum)8
Gem7
Other16

Conclusions

Findings suggest that, in US clinical practice, there is substantial heterogeneity in the tx of pts with mTNBC. Pts had a median OS 

Clinical trial identification

Legal entity responsible for the study

Genentech, Inc.

Funding

Genentech, Inc.

Disclosure

P. Bajaj, C. Reyes, A. Stein, P. Cortazar: Employee of Genentech, Inc. and owner of Roche stock. D. Latremouille-Viau, A. Guerin: Employee of Analysis Group, Inc., which has received consulting fees and research funding from Genentech, Inc. All other authors have declared no conflicts of interest.